Hell Of A Life (Album Version (Edited))
YouTube video by Kanye West - Topic
youtu.be
September 22, 2026 at 6:34 AM
www.youtube.com/watch?v=GLmd... an all-timer. Awesome vibe and great storytelling.
Coheed And Cambria - Delirium Trigger
YouTube video by Equal Vision Records
www.youtube.com
April 9, 2025 at 12:22 AM
www.youtube.com/watch?v=GLmd... an all-timer. Awesome vibe and great storytelling.
Hell Of A Life (Album Version (Edited))
YouTube video by Kanye West - Topic
youtu.be
May 5, 2026 at 7:04 PM
August 30, 2024 at 1:55 PM
Breaking News: ( NASDAQ: #GLMD ) Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is One of Tuesday Morning's Most Active Stocks
#StockMarket #News
#StockMarket #News
September 17, 2024 at 6:35 PM
Breaking News: ( NASDAQ: #GLMD ) Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is One of Tuesday Morning's Most Active Stocks
#StockMarket #News
#StockMarket #News
ちゃっぴーのお絵描き配信準備動画⬇️⬇️
youtube.com/watch?v=glmd...
#Vtuber #お絵描き配信 #準備中 #イラスト #Live2dｱﾊﾞﾀｰ #Live2D #立ち絵 #モデリング
youtube.com/watch?v=glmd...
#Vtuber #お絵描き配信 #準備中 #イラスト #Live2dｱﾊﾞﾀｰ #Live2D #立ち絵 #モデリング
December 15, 2024 at 2:02 PM
ちゃっぴーのお絵描き配信準備動画⬇️⬇️
youtube.com/watch?v=glmd...
#Vtuber #お絵描き配信 #準備中 #イラスト #Live2dｱﾊﾞﾀｰ #Live2D #立ち絵 #モデリング
youtube.com/watch?v=glmd...
#Vtuber #お絵描き配信 #準備中 #イラスト #Live2dｱﾊﾞﾀｰ #Live2D #立ち絵 #モデリング
BREAKING NEWS: ( NASDAQ: #GLMD ) Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
#StockMarket #News
#StockMarket #News
September 19, 2024 at 2:15 PM
BREAKING NEWS: ( NASDAQ: #GLMD ) Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
#StockMarket #News
#StockMarket #News
$SLP Q2 revenue up 8% to $24.3M, gross margin 66%, EPS $0.22, showing stronger profitability and leverage. $SLP $MGNX $TLX $TLSI $ONCO $MIST $DRMA $PSTV $GLMD $TELO
www.biopharmcatalyst.com/news/2026/si...
www.biopharmcatalyst.com/news/2026/si...
Pre-Market Updates 04/10/26
export-download.canva.com
April 10, 2026 at 12:40 PM
$SLP Q2 revenue up 8% to $24.3M, gross margin 66%, EPS $0.22, showing stronger profitability and leverage. $SLP $MGNX $TLX $TLSI $ONCO $MIST $DRMA $PSTV $GLMD $TELO
www.biopharmcatalyst.com/news/2026/si...
www.biopharmcatalyst.com/news/2026/si...
$BCDA director Richard Krasno bought shares, signaling confidence as the CardiALLO trial proceeded after safety data.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pe...
$BCDA $IFRX $TVGN $ITRM $KNSA $GNFT $PTPI $ $GLMD
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pe...
$BCDA $IFRX $TVGN $ITRM $KNSA $GNFT $PTPI $ $GLMD
April 29, 2025 at 8:59 PM
$BCDA director Richard Krasno bought shares, signaling confidence as the CardiALLO trial proceeded after safety data.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pe...
$BCDA $IFRX $TVGN $ITRM $KNSA $GNFT $PTPI $ $GLMD
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pe...
$BCDA $IFRX $TVGN $ITRM $KNSA $GNFT $PTPI $ $GLMD
Pre-market Volatility Alert! 📉🚀 (Apr 9, 2026)
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
April 9, 2026 at 1:02 PM
Pre-market Volatility Alert! 📉🚀 (Apr 9, 2026)
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
#$GLMD developed a breakthrough brain-penetrating formulation of Aramchol in partnership with Barcode Nanotech, using proprietary lipid nanoparticles to deliver the SCD1 inhibitor across the blood-brain barrier for CNS diseases.
prismmarketview.com/companies/ga...
prismmarketview.com/companies/ga...
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Ar
prismmarketview.com
April 9, 2026 at 8:44 PM
#$GLMD developed a breakthrough brain-penetrating formulation of Aramchol in partnership with Barcode Nanotech, using proprietary lipid nanoparticles to deliver the SCD1 inhibitor across the blood-brain barrier for CNS diseases.
prismmarketview.com/companies/ga...
prismmarketview.com/companies/ga...
Michel Alcoforado chateia herdeiros que não fazem nada: 'Parece que revelei um segredo' www.youtube.com/watch?v=GLMD...
Michel Alcoforado chateia herdeiros que não fazem nada: 'Parece que revelei um segredo'
YouTube video by Rádio CBN
www.youtube.com
August 31, 2026 at 1:19 PM
Michel Alcoforado chateia herdeiros que não fazem nada: 'Parece que revelei um segredo' www.youtube.com/watch?v=GLMD...
Galmed Pharmaceuticals (NASDAQ: GLMD) Undergoes Reverse Stock Split: What Investors Need to Know www.stocks2buy.net/newsitems/ga...
Galmed Pharmaceuticals (NASDAQ: GLMD) Undergoes Reverse Stock Split: What Investors Need to Know
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for liver diseases and related metabolic conditions. On August 19, 2026, the…
www.stocks2buy.net
August 20, 2026 at 3:16 PM
Galmed Pharmaceuticals (NASDAQ: GLMD) Undergoes Reverse Stock Split: What Investors Need to Know www.stocks2buy.net/newsitems/ga...
#GLMD Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
https://www.stocktitan.net/news/GLMD/galmed-announces-successful-first-in-human-proof-of-concept-clinical-s3a12jx6hdoj.html
https://www.stocktitan.net/news/GLMD/galmed-announces-successful-first-in-human-proof-of-concept-clinical-s3a12jx6hdoj.html
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
Galmed Pharmaceuticals (NASDAQ: GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human, prospective single-arm feasibility study of a novel intraoperative colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery at three leading medical centers in Israel.The study demonstrated that quantitative measurement of colon tissue compliance using a novel ex-vivo methodology was technically feasible, with successful measurements in all 32 patients and no measurement failures or procedure-related technical issues. These results establish a clinical foundation for continued development of an intraoperative device to provide surgeons with objective, real-time tissue quality data, complementing Colospan’s CG-100 intraluminal bypass device and supporting Galmed’s strategy to build a diversified GI oncology and colorectal surgery portfolio.
www.stocktitan.net
August 19, 2026 at 11:00 AM
#GLMD Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
https://www.stocktitan.net/news/GLMD/galmed-announces-successful-first-in-human-proof-of-concept-clinical-s3a12jx6hdoj.html
https://www.stocktitan.net/news/GLMD/galmed-announces-successful-first-in-human-proof-of-concept-clinical-s3a12jx6hdoj.html
Trading Halted for $GLMD Galmed Pharmaceuticals Ltd | at 19:50:00.000 ET on NASDAQ | Halt - News Pending | 2026-08-18
August 18, 2026 at 11:51 PM
Trading Halted for $GLMD Galmed Pharmaceuticals Ltd | at 19:50:00.000 ET on NASDAQ | Halt - News Pending | 2026-08-18
$GLMD — Foreign Issuer Report
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
August 17, 2026 at 9:30 PM
$GLMD — Foreign Issuer Report
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
$AMLX to share Phase 3 LUCIDITY study data on avexitide for post-bariatric hypoglycemia Aug 18, 2026; webcast at 8am ET. $EYPT $ADIL $CUE $CTXR $ARGX $FDMT $GLMD $BTAI $SKYE
www.biopharmcatalyst.com/news/2026/ad...
www.biopharmcatalyst.com/news/2026/ad...
Daily Updates 08/17/26
export-download.canva.com
August 17, 2026 at 8:30 PM
$AMLX to share Phase 3 LUCIDITY study data on avexitide for post-bariatric hypoglycemia Aug 18, 2026; webcast at 8am ET. $EYPT $ADIL $CUE $CTXR $ARGX $FDMT $GLMD $BTAI $SKYE
www.biopharmcatalyst.com/news/2026/ad...
www.biopharmcatalyst.com/news/2026/ad...
Meilleure réponse ever : bsky.app/profile/glmd...
PRESIDENT DEMISSION
July 16, 2026 at 7:29 PM
Meilleure réponse ever : bsky.app/profile/glmd...
News; ( NASDAQ: #GLMD ) Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
July 16, 2026 at 4:01 PM
GLMD
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
July 16, 2026 at 6:12 PM
GLMD
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
#GLMD Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
Galmed's Aramchol Formulation Redirects Drug Toward Heart Tissue
Traditional Aramchol accumulates 80%-90% in the liver; the collaboration's platform screens hundreds of nanoparticle candidates for cardiac delivery.
www.stocktitan.net
July 16, 2026 at 11:30 AM
#GLMD Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Earnings Results
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports. Galmed Pharmaceuticals Stock…
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports. Galmed Pharmaceuticals Stock…
Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Earnings Results
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports. Galmed Pharmaceuticals Stock Performance Shares of GLMD stock opened at $0.57 on Friday. The stock’s fifty day moving average is $0.60 and its two-hundred day moving average [...]
news-area.com
July 10, 2026 at 11:28 PM
Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Earnings Results
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports. Galmed Pharmaceuticals Stock…
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports. Galmed Pharmaceuticals Stock…
